Denali amends Biogen pacts; milestones unchanged, Biogen waives option rights

Denali Therapeutics Inc.

Amendment to LRRK2 Collaboration and ROFN agreements executed Aug 17, 2023.
Milestone schedule revised but total eligible milestone value remains unchanged.
Biogen waives option to second program and rights of first negotiation for two TV-enabled programs.
Relates to prior announcements on June 5, 2023 (LRRK2) and April 12, 2023 (ATV:Aβ).
Other terms of original agreements remain in full force per Denali.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Denali Therapeutics Inc. amended Amendment with Biogen MA, Inc. and Biogen International GmbH (effective 2023-08-17).

Action: amendment
Agreement: license
Counterparty: Biogen MA, Inc. and Biogen International GmbH
Effective: 2023-08-17

Exact text from the filing

on August 17, 2023, Denali Therapeutics Inc., (“Denali” or “we”) and Biogen MA, Inc. and Biogen International GmbH, (collectively, “Biogen”) executed an Amendment to the Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement (the “Amendment”).

View on SEC.gov

Browse all material agreements →

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-23-000131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.